SCHEMBL22959040

SCHEMBL22959040

IN1CC2CC(C1)N2I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16676610 0.80
SCHEMBL20153153 0.69
SCHEMBL22812179 0.69
SCHEMBL21158880 0.69
SCHEMBL20069489 0.69
SCHEMBL23555261 0.69
SCHEMBL25165115 0.67
SCHEMBL23555142 0.66
SCHEMBL21599172 0.65
SCHEMBL18862641 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4289428-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF Applied Pharmaceutical Science, Inc. (CN) 2023-12-13 EP disclosed
WO-2023280073-A1 METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND 北京志健金瑞生物医药科技有限公司 2023-01-12 WO disclosed
WO-2022262797-A1 COMBINATION OF AN ERK INHIBITOR AND A KRAS INHIBITOR AND USES THEREOF SHANGHAI ANTENGENE CORPORATION LIMITED (CN) 2022-12-22 WO disclosed
US-20220218700-A1 COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA BAYER AKTIENGESELLSCHAFT (DE) 2022-07-14 US disclosed
EP-3992197-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUNDS, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Applied Pharmaceutical Science, Inc. (CN) 2022-05-04 EP disclosed
WO-2022012623-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2022-01-20 WO disclosed
EP-3845531-A1 SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Applied Pharmaceutical Science, Inc. (CN) 2021-07-07 EP disclosed
WO-2021023209-A1 NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUNDS, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 北京志健金瑞生物医药科技有限公司 2021-02-11 WO disclosed